News & Updates

Which factors improve survival in ICI-treated patients with NSCLC?
Which factors improve survival in ICI-treated patients with NSCLC?
25 Apr 2023

The survival benefit derived from using immune checkpoint inhibitors (ICIs) is more evident in patients with advanced nonsmall cell lung cancer (NSCLC) who received first-line therapy, showed low neutrophil/lymphocyte ratio (NLR), and had no history of hormone use following initial treatment, suggests a recent study.

Which factors improve survival in ICI-treated patients with NSCLC?
25 Apr 2023
Patients at risk for BE worried over EAC but rarely undergoes screening: study
Patients at risk for BE worried over EAC but rarely undergoes screening: study
25 Apr 2023

Patients who are prone to Barrett’s esophagus (BE), specifically those belonging to racial and ethnic minorities, express concern about developing esophageal adenocarcinoma (EAC), reveals a study. However, they seldom go through screening and lack awareness of screening recommendations.

Patients at risk for BE worried over EAC but rarely undergoes screening: study
25 Apr 2023
Psilocybin shows therapeutic potential for depression
Psilocybin shows therapeutic potential for depression
24 Apr 2023

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

Psilocybin shows therapeutic potential for depression
24 Apr 2023
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
20 Apr 2023